ID
45506
Description
Principal Investigator: Matthew Meyerson, MD, PhD, Broad Institute, Cambridge MA, Dana Farber Cancer Institute, Boston MA, USA MeSH: Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000488 Lung carcinoma is the leading cause of cancer death in the United States and world-wide; lung adenocarcinoma is the most common cause of lung cancer. Pilot studies of lung adenocarcinoma with hybrid-capture based whole exome sequencing will enable us to identify new targets for therapy and improve diagnosis. We will analyze a blend of whole exome and whole genome sequencing data as well as copy number and somatic mutation calls for 200 tumor and matched normal controls. When completed this study will represent the most comprehensive lung adenocarcinoma genome dataset to date.
Link
Keywords
Versions (2)
- 11/9/22 11/9/22 - Dr. med. Lucy Kessler
- 12/13/22 12/13/22 - Kristina Keller
Copyright Holder
Matthew Meyerson, MD, PhD, Broad Institute, Cambridge MA, Dana Farber Cancer Institute, Boston MA, USA
Uploaded on
December 13, 2022
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
dbGaP phs000488 Genomic Sequencing of Lung Adenocarcinoma
Subject ID and consent group of participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- Sample ID, subject ID, and sample use variables obtained from participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- Subject ID, age, ethnicity, pathological diagnosis of tumors, tumor stage, and smoking status of participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- Sample ID, analyte type, tumor status, hospital diagnosis, and body site where samples were obtained from participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
Similar models
Subject ID and consent group of participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- Sample ID, subject ID, and sample use variables obtained from participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- Subject ID, age, ethnicity, pathological diagnosis of tumors, tumor stage, and smoking status of participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
- Sample ID, analyte type, tumor status, hospital diagnosis, and body site where samples were obtained from participants with lung adenocarcinoma and involved in the "Genomic Sequencing of Lung Adenocarcinoma" project.
C0021430 (UMLS CUI [1,2])